RA
BIO icon

Rovida Advisors’s Bio-Rad Laboratories Class A BIO Stock Holding History

Rovida Advisors’s Portfolio BIO Stock Details BIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q2 		– Sell
-25,000
Closed -$8.76M – 48
2020
Q1 		$8.76M Buy
+25,000
New +$9.19M 4.12% 8
2019
Q4 		– Sell
-25,000
Closed -$8.31M – 59
2019
Q3 		$8.31M Buy
25,000
+5,000
+25% +$1.63M 0.49% 38
2019
Q2 		$6.25M Buy
20,000
+4,000
+25% +$1.2M 0.37% 36
2019
Q1 		$4.89M Buy
+16,000
New +$4.32M 0.33% 37

Other funds holding BIO

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
American Century Companies
American Century Companies Kansas City, Missouri $194B AUM 35% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return
ACM
Atlanta Capital Management Atlanta, Georgia $22.5B AUM 9.67% 1-Year Est. Return
Brown Advisory
Brown Advisory Baltimore, Maryland $60.9B AUM 15.24% 1-Year Est. Return
UBS AM
UBS AM Chicago, Illinois $481B AUM 26.39% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return

Rovida Advisors's BIO Position: Q2 2020 in Review

Rovida Advisors sold out of Bio-Rad Laboratories Class A (BIO) in Q2 2020, closing a stake of 25,000 shares — an estimated $8.76M sold.

Rovida Advisors first reported a position in BIO in Q1 2019 and held it in 4 quarters. The position peaked at $8.76M in Q1 2020. 469 funds tracked by Wall St. Rank hold BIO as of Q2 2020.

  • Rovida Advisors reported no remaining Bio-Rad Laboratories Class A position as of Q2 2020 after selling out during the quarter.
  • Rovida Advisors sold 25,000 Bio-Rad Laboratories Class A shares in Q2 2020, an estimated $8.76M.
  • Rovida Advisors first reported a position in Bio-Rad Laboratories Class A in Q1 2019 and held it in 4 quarters.
  • Rovida Advisors's Bio-Rad Laboratories Class A position peaked at $8.76M in Q1 2020.
  • 469 funds tracked by Wall St. Rank held Bio-Rad Laboratories Class A as of Q2 2020.

Based on Rovida Advisors's 13F filing for Q2 2020, filed 12 Aug 2020.